Table 1 Baseline characteristics of patients in ASCVD events study before and after PSM

Patients, n

487

971

446

446

Sex, n (%)

 < 0.001

0.693

 Male

426 (87.5%)

580 (59.7%)

385 (86.3%)

389 (87.2%)

 Female

61 (12.5%)

391 (40.3%)

61 (13.7%)

57 (12.8%)

Age, n (%)

0.007

0.460

 < 65

224 (46.0%)

375 (38.6%)

243 (54.5%)

232 (52.0%)

 ≥ 65

263 (54.0%)

596 (61.4%)

203 (45.5%)

214 (48.0%)

Body mass index (kg/m²), mean (SD)

22.4 (3.0)

22.6 (3.0)

0.115

22.4 (3.0)

22.6 (3.0)

0.528

Cancer characteristics, n (%)

Stages

 < 0.001

0.821

 Stage III

138 (28.3%)

176 (18.1%)

121 (27.1%)

118 (26.5%)

 Stage IV

349 (71.7%)

795 (81.9%)

325 (72.9%)

328 (73.5%)

Pathological types

 < 0.001

0.108

 Adenocarcinoma

217 (44.6%)

742 (76.4%)

216 (48.4%)

247 (55.4%)

 Squamous cell carcinoma

235 (48.3%)

175 (18.0%)

196 (43.9%)

167 (37.4%)

 Other^a

35 (7.2%)

54 (5.6%)

34 (7.6%)

32 (7.2%)

Cardiovascular risk factors, n (%)

 Hypertension

152 (31.2%)

313 (32.2%)

0.693

144 (32.3%)

171 (38.3%)

0.059

 Diabetes

45 (9.2%)

63 (6.5%)

0.058

39 (8.7%)

42 (9.4%)

0.727

Smoking index, n (%)

 < 0.001

0.270

 ≤ 400

284 (58.3%)

779 (80.2%)

268 (60.1%)

284 (63.7%)

 > 400

203 (41.7%)

192 (19.8%)

178 (39.9%)

162 (36.3%)

Hyperlipidemia

68 (14.0%)

169 (17.4%)

0.093

65 (14.6%)

59 (13.2%)

0.561

History of cardiovascular disease, n (%)

47 (9.7%)

68 (7.0%)

0.077

42 (9.4%)

49 (11.0%)

0.439

Cardiovascular medications, n (%)

 Statins

35 (7.2%)

59 (6.1%)

0.415

31 (7.0%)

36 (8.1%)

0.525

 Aspirin

24 (4.9%)

47 (4.8%)

0.941

22 (4.9%)

21 (4.7%)

0.876

Other antiplatelet therapies

19 (3.9%)

34 (3.5%)

0.700

17 (3.8%)

16 (3.6%)

0.859

Chest radiation therapy, n (%)

107 (22.0%)

174 (17.9%)

0.064

98 (22.0%)

93 (20.9%)

0.683

Cycles of ICI, mean (SD)

9.1 (7.7)

9.4 (7.9)

ICIs type, n (%)

 PD-1 antibody

450 (92.4%)

411 (92.2%)

 PD-L1 antibody

35 (7.2%)

33 (7.4%)

 CTLA-4 antibody

2 (0.4%)

2 (0.4%)